Bladder Cancer
Bladder cancer remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy has been the standard therapy for metastatic bladder cancer but has had limited success in improving disease outcomes. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we can provide the best vaccine development services for bladder cancer.
Introduction to Bladder Cancer
Like many cancers, bladder cancer is a disease of old age. Risk factors for bladder cancer include smoking, dyes, rubber, textiles, paints, and exposure to chemicals.
Therapy for Bladder Cancer
Conventional immunotherapies for bladder cancer include the BCG vaccine, and newer therapies include immune checkpoint blocking as well as agonists and vaccines designed to initiate an anti-tumor immune response. Intravesical BCG immunotherapy remains the gold standard therapy, but there are exciting possibilities for improving outcomes by combining BCG with other immunomodulatory approaches.
Bladder Cancer Vaccine
Cancer vaccines are designed to initiate a T-cell response against tumor antigens by inducing the activation of antigen-presenting cells (APCs), potentially mediating tumor cell lysis.
Bladder Cancer Vaccine with Different Routes of Administration
Different drug delivery routes have their advantages, and the specific selection needs to be verified by experiments. Probiotics have been reported to have certain systemic cancer therapy effects. For example, in bladder cancer, the use of lactic acid bacteria (LAB) as a carrier for oral vaccines can deliver foreign antigens to the intestinal immune system.
- Intravenous administration
- Intraperitoneal administration
- Intramuscular administration
- Oral administration
- Subcutaneous administration
Bladder Cancer Vaccine with Different Targeting Site
Tumor antigen release marks the beginning of the tumor immune cycle and is critical to the outcome of tumor immunotherapy. Immunotherapy approaches rely primarily on the delivery or in-situ production of tumor antigens to activate autologous anti-cancer immune response. In particular, immunogenic cell death (ICD) of tumor cells is an effective strategy to promote tumor antigen release, thereby enhancing tumor immunogenicity.
Our Service
Therapeutic cancer vaccines that work in concert with other therapies have great potential to cure cancer. Alfa Cytology provides a variety of services related to bladder cancer vaccine development by optimizing multiple aspects.
Bladder cancer begins with a mutation in the bladder cells' DNA. Most bladder cancers are found early and have a high cure rate, but it is still possible for them to recur. Alfa Cytology is committed to the research and development of cancer vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.